Microsoft is pushing its artificial-intelligence strategy in two distinct directions at once, but investors are still waiting for the payoff. At the Build 2026 developer conference, the software giant unveiled a clear pivot toward AI agents that run broadly across Windows devices rather than being locked to specialized Copilot+ hardware. The shift, centered on features like Microsoft Execution Containers and a new small language model embedded in Edge, signals that Redmond wants AI to become a pervasive layer over its existing software stack—not just a standalone add-on.
That architectural vision gained immediate real-world validation on the other side of the Atlantic. The UK’s National Health Service has signed one of the largest public-sector technology deals in history, equipping half a million employees with Microsoft 365 Copilot by October 2026. A pilot program found the tool saved clinical staff an average of 43 minutes of administrative work per day. The NHS is committing roughly £120 million from its digital budget over three years and expects the productivity gains to cover that cost within 18 months. Individual hospitals can also build custom AI agents through the included Copilot Studio.
The commercial momentum is undeniable: Microsoft’s AI business is now generating an annualized revenue run rate of $37 billion, up 123% year over year, while cloud revenue climbed 40%. Yet the price tag for that growth is staggering. The company plans to pour around $190 billion into datacenter infrastructure in 2026 alone, a figure that is compressing free cash flow and squeezing margins. Those capital demands, combined with an ongoing Federal Trade Commission probe into Microsoft’s cloud-licensing and software-bundling practices, have kept a lid on the stock.
Shares ended last week at €361.70 in Frankfurt, a drop of 8.73% on the week, bringing the year-to-date decline to 10.38%. The primary article’s Monday open saw the stock at €358.15, down nearly 1%, as the initial euphoria over the NHS deal faded. Technically, the picture is mixed: the price sits above its 50-day moving average of €349.95 but below the 200-day line of €391.25. The relative strength index of 49.5 points to neither overbought nor oversold conditions.
Should investors sell immediately? Or is it worth buying Microsoft?
Despite the near-term headwinds, analysts remain upbeat. TD Cowen praised the launch of seven new cost-efficient AI models, while Cantor Fitzgerald framed Microsoft as evolving into a comprehensive enterprise platform. The company will pay a dividend of $0.91 per share in June 2026, representing a comfortable payout ratio of 21%.
For the developer community, Build 2026 offered more concrete hooks. The new Windows Development Skills and an intelligent Terminal bring AI agents directly into the command line, providing context-aware assistance. WSL Containers give Windows 11 a built-in runtime for Linux containers, reducing reliance on third-party tools. And the upcoming “Work IQ” APIs, due to become generally available in June, will let developers tap into Microsoft 365 data streams, giving agents a shared understanding of corporate workflows.
The NHS project could open the door to more government contracts—the UK’s departments for work and finance are already testing Copilot internally. But the ultimate test for Microsoft’s dual-track AI strategy will be whether developers embrace the agent-based tools and whether enterprise customers like the NHS see the promised productivity gains materialize. Until then, the stock remains caught between a long-term narrative of AI dominance and the short-term drag of colossal spending and regulatory scrutiny.
Ad
Microsoft Stock: Buy or Sell?! New Microsoft Analysis from June 8 delivers the answer:
The latest Microsoft figures speak for themselves: Urgent action needed for Microsoft investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 8.
Microsoft: Buy or sell? Read more here...
